10x Genomics [TXG] vs Veeva Systems [VEEV] Detailed Stock Comparison

10x Genomics Inc.

NASDAQ
Loading...

Veeva Systems Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: 10x Genomics Inc. wins in 5 metrics, Veeva Systems Inc. wins in 14 metrics, with 0 ties. Veeva Systems Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric 10x Genomics Inc. Veeva Systems Inc. Better
P/E Ratio (TTM) -63.09 29.57 Veeva Systems Inc.
Price-to-Book Ratio 3.54 3.66 10x Genomics Inc.
Debt-to-Equity Ratio 10.59 1.33 Veeva Systems Inc.
PEG Ratio 0.93 1.22 10x Genomics Inc.
EV/EBITDA -37.16 20.16 Veeva Systems Inc.
Profit Margin (TTM) -6.77% 28.45% Veeva Systems Inc.
Operating Margin (TTM) -9.42% 29.41% Veeva Systems Inc.
EBITDA Margin (TTM) N/A 29.41% N/A
Return on Equity -5.78% 13.93% Veeva Systems Inc.
Return on Assets (TTM) -6.40% 7.25% Veeva Systems Inc.
Free Cash Flow (TTM) $130.12M $1.42B Veeva Systems Inc.
1-Year Return 177.04% -43.54% 10x Genomics Inc.
Price-to-Sales Ratio (TTM) 4.39 8.29 10x Genomics Inc.
Enterprise Value $2.38B $19.85B Veeva Systems Inc.
EV/Revenue Ratio 3.71 6.21 10x Genomics Inc.
Gross Profit Margin (TTM) 68.09% 74.46% Veeva Systems Inc.
Revenue per Share (TTM) $5 $20 Veeva Systems Inc.
Earnings per Share (Diluted) $-0.35 $5.45 Veeva Systems Inc.
Beta (Stock Volatility) 2.17 1.10 Veeva Systems Inc.
Short % of Float 20.38% 3.90% Veeva Systems Inc.

10x Genomics Inc. vs Veeva Systems Inc. Stock Performance Analysis

Loading Price Chart...

TXG
VEEV

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
10x Genomics Inc.11.72%10.42%51.98%93.05%104.44%93.86%
Veeva Systems Inc.1.65%-3.03%2.08%-12.47%-26.32%-26.12%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
10x Genomics Inc.177.04%-50.37%-85.17%-44.82%-44.82%-44.82%
Veeva Systems Inc.-43.54%-20.25%-47.98%374.26%259.41%259.41%

Performance & Financial Health Analysis: 10x Genomics Inc. vs Veeva Systems Inc.

MetricTXGVEEV
Market Information
Market Cap i$2.82B$26.49B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i2,733,1602,223,070
90 Day Avg. Volume i2,471,3332,094,990
Last Close$32.22$162.17
52 Week Range$10.17 - $35.65$148.05 - $310.50
% from 52W High-9.61%-47.77%
All-Time High$208.99 (Jun 28, 2021)$343.96 (Aug 02, 2021)
% from All-Time High-84.58%-52.85%
Growth Metrics
Quarterly Revenue Growth0.01%0.16%
Quarterly Earnings Growth0.01%0.25%
Financial Health
Profit Margin (TTM) i-0.07%0.28%
Operating Margin (TTM) i-0.09%0.29%
Return on Equity (TTM) i-0.06%0.14%
Debt to Equity (MRQ) i10.591.33
Cash & Liquidity
Book Value per Share (MRQ)$6.24$44.05
Cash per Share (MRQ)$4.10$40.17
Operating Cash Flow (TTM) i$136.05M$1.42B
Levered Free Cash Flow (TTM) i$148.39M$1.05B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 10x Genomics Inc. vs Veeva Systems Inc.

MetricTXG (Apr 26, 2026)VEEV (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-63.0929.57
Forward P/E i110.4016.30
PEG Ratio i0.931.22
Price to Sales (TTM) i4.398.29
Price to Book (MRQ) i3.543.66
Market Capitalization
Market Capitalization i$2.82B$26.49B
Enterprise Value i$2.38B$19.85B
Enterprise Value Metrics
Enterprise to Revenue i3.716.21
Enterprise to EBITDA i-37.1620.16
Risk & Other Metrics
Beta i2.171.10
Book Value per Share (MRQ) i$6.24$44.05

Financial Statements Comparison: 10x Genomics Inc. vs Veeva Systems Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTXG (2025)VEEV (2026)
Revenue/Sales i642.82M3.20B
Cost of Goods Sold i198.94M782.02M
COGS % of Revenue i30.9%24.5%
Gross Profit i443.88M2.41B
Gross Margin i69.1%75.5%
Research & Development i238.63M767.39M
Operating Income (EBIT) i-110.89M916.37M
Operating Margin i-17.2%28.7%
EBITDA i-45.99M944.36M
EBITDA Margin i-7.2%29.6%
Pre-Tax Income i-39.91M1.19B
Pre-Tax Income % of Revenue i-6.2%37.4%
Income Tax i3.64M285.60M
Income Tax % of Revenue i0.6%8.9%
Net Income (Profit) i-43.54M908.91M
Profit Margin i-6.8%28.4%

Balance Sheet & Liquidity Metrics

MetricTXG (2025)VEEV (2026)
Cash & Equivalents i473.97M1.42B
Total Current Assets i684.45M8.00B
Total Current Assets % of Revenue i106.5%250.3%
Total Current Liabilities i153.45M1.64B
Total Current Liabilities % of Revenue i23.9%51.2%
Long-Term Debt i73.38M83.71M
Long-Term Debt % of Revenue i11.4%2.6%
Total Shareholders Equity i796.33M7.21B
Retained Earnings i-1.51B4.36B
Retained Earnings % of Revenue i-235.0%136.6%
Property, Plant & Equipment i60.45M0

Cash Flow Statement Comparison

MetricTXG (2025)VEEV (2026)
Operating Cash Flow i141.48M1.46B
Operating Cash Flow % of Revenue i22.0%45.6%
Capital Expenditures i-5.94MN/A
Free Cash Flow i130.12M1.42B
FCF Margin i20.2%44.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-169.95M

Short Interest & Institutional Ownership Analysis

MetricTXGVEEV
Shares Short i16.47M5.82M
Short Ratio i6.842.75
Short % of Float i20.38%3.90%
Shares Outstanding i127.69M163.78M
Float Shares i115.49M149.83M
% Held by Insiders i1.81%8.57%
% Held by Institutions i108.01%89.44%
% Held by Public i-9.82%1.99%

Dividend Analysis & Yield Comparison: 10x Genomics Inc. vs Veeva Systems Inc.

MetricTXGVEEV
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A